vatalanib has been researched along with doxazosin mesylate in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (doxazosin mesylate) | Trials (doxazosin mesylate) | Recent Studies (post-2010) (doxazosin mesylate) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 24 | 0 | 15 |
| Protein | Taxonomy | vatalanib (IC50) | doxazosin mesylate (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouvier, M; Deng, H; Dsouza, NR; Johnson, ME; Lee, H; Ren, J | 1 |
1 other study(ies) available for vatalanib and doxazosin mesylate
| Article | Year |
|---|---|
Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions.
Topics: Adenoviridae; Adenovirus E3 Proteins; Antiviral Agents; Dose-Response Relationship, Drug; Drug Discovery; HLA-A2 Antigen; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Small Molecule Libraries; Structure-Activity Relationship | 2018 |